1.97 Billion USD Deal Between Heng Rui and Merck for Lp(a) Inhibitor

Recently, Heng Rui Pharmaceuticals signed an exclusive licensing agreement with Merck for the Lp(a) inhibitor HRS-5346, with a total transaction value reaching $1.97 billion. This collaboration has generated significant buzz within the pharmaceutical industry, attracting considerable attention from professionals.

On March 25, Heng Rui announced that it achieved a record high upfront payment of $200 million, marking a significant milestone in its business development (BD) efforts. With this deal, Heng Rui has solidified its presence in the competitive and promising Lp(a) therapy market.

The agreement grants Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 globally, excluding Greater China. In addition to the upfront payment, Heng Rui stands to earn up to $1.77 billion in milestone payments based on specific development, registration, and commercialization achievements. If HRS-5346 is approved, Heng Rui will also receive royalties on net sales.

HRS-5346 is currently undergoing Phase II clinical trials in China, and this partnership injects significant funding into Heng Rui's R&D operations, alleviating financial pressures and accelerating its innovative drug development. Furthermore, leveraging Merck's global network will enhance Heng Rui's ability to expedite HRS-5346's overseas development and market expansion.

This transaction sets a new record for Heng Rui’s upfront payments in recent years. In addition, Heng Rui has made several overseas licensing agreements to accelerate the globalization of its innovative drugs.

With this partnership, Heng Rui has reaffirmed its multi-target strategy, marking a significant upgrade in its internationalization efforts and integration into the global drug innovation network.